**Transcatheter Aortic Valve Implantation**

192 Aortic Valve

[38] Okamura H, Yamaguchi A, Noguchi K, Naito K, Yuri K, Adachi H. Hemodynamics and

[39] Girard SE, Miller FA, Montgomery S, Edwards WD, Tazelaar HD, Malouf JF, Seward JB,

*Thorac.* 2010;18(5):450-5

*Am J Cardiol.* 2001;82:111-114

outcomes of aortic valve replacement with a 17- or 19-mm valve. *Asian Cardiovas* 

Orszulak TA. Outcome of reoperation for aortic valve prosthesis-patient mismatch.

**10** 

**Current Indications for** 

*University of Rostock* 

*Germany* 

**Transcatheter Aortic Valve Implantation** 

Rising life expectancy results in an increase of degenerative and neoplastic diseases. Population-based observational studies report that 1% to 2% of patients older than 65 years have moderate-to-severe aortic stenosis (AS) (Nkomo *et al.*, 2006). Surgical aortic valve replacement (AVR) dates back to 1960 and is currently the only treatment option for severe AS that has been shown to improve survival, regardless of age (Kvidal *et al.*, 2000). In the ideal candidate, surgical AVR has an estimated operative mortality of 4% (Kvidal *et al.*, 2000). Unfortunately, up to one-third of patients with severe AS are ineligible for corrective valve surgery, either because of advanced age or the presence of multiple comorbidities (Iung *et al.*, 2005). Current treatment options for those patients not offered surgery include medical treatment or percutaneous balloon aortic valvuloplasty, although neither has been

> 0 40 50 60 70 80 **Age (Years)**

Fig. 1. Survival of medically treated symptomatic AS (Ross J Jr. & Braunwald E, 1965)

**1. Introduction** 

100

80

 Latent Period (Increasing Obstruction, Myocardial Overload)

60

40

20

0

Tim C. Rehders, Christoph A. Nienaber and Hüseyin Ince

 Onset Severe Symptoms

Angina

0 2 4 6 **Avg. Survival (Yrs)**

Syncope Failure

Ibrahim Akin, Stephan Kische, Henrik Schneider,
